drugset / Trial / NCT06541639
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
Phase 1
Recruiting
78 enrolled
Peking University
Everest Medicines (China) Co.,Ltd. · collabShanghai Cancer Centre · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment. The main questions to answer are: Safety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.
Timeline
- Start
- 2025-03-04
- Primary completion
- 2028-03
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EVM16 | Unknown | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |